ASCO 2022 Annual Meeting encapsulated the recent developments in the oncology dimension, it convenes cancer researchers from all over the world and provides a forum for the presentation of results of clinical trials that can affect practice, change the direction of future research, or have an impact on policy.
Various ASCO abstract 2022 presented in the conference demonstrated the strategic collaborations, significantly growing pipeline, oncology market trends, and the dynamism of the healthcare vertical.
- Major data readout of potential ADCs included Enhertu gearing up for the Urothelial Carcinoma Market. The abstract indicated a study where Enhertu with Opdivo exhibited clinical efficacy with an ORR of 36.7% in HER2+ urothelial cancer in the Phase Ib study. On the second day of ASCO GU 2022, the rapid abstract session highlighted the results from the DS8201-A-U105 trial of Enhertu (trastuzumab deruxtecan) with Opdivo (nivolumab) in patients with HER2 expressing urothelial carcinoma.
- The results which were presented at the ASCO GU 2022 symposium were from cohort 3 of the U105 Phase Ib trial, and the objective response rate by independent central review (ICR) was 36.7%, with 13.3% of patients experiencing complete response (CR) and 23.3% of patients experiencing a partial response. The median duration of response (DoR) was 13.1 months, and the progression-free survival (PFS) was 1.9 months.
- An analysis of Braftovi in a triplet combination after adding Opdivo in Phase I/II study sponsored by BMS/Pfizer in collaboration with NCI was presented at the ASCO 20200 annual meeting.
- The study evaluated the triplet combination of encorafenib + cetuximab + nivolumab in MSS mCRC patients who have received prior treatment with at least one, but not more than two systemic chemotherapy regimens for mCRC. In September 2021, USFDA approved the Braftovi Erbitux combination to treat BRAF V600E mutated adult patients after prior therapy for mCRC based on the results from the BEACON Colorectal Cancer trial.
The approval of the combination was not indicated in patients who were MSS, but the ongoing study is evaluating BRAF V600E who have MSS status.
- Another analysis was done for Janssen and Legend Biotech's CAR-T cell therapy which demonstrated durable responses in the earlier setting of Multiple Myeloma, the study results were based on the CARTITUDE 2 trial. Carvykti/Cilta-cel is a newly approved CAR-T cell therapy for adults with relapsed or refractory multiple myeloma (FDA approved in February 2022).
- The findings of the CARTITUDE 2 trial were presented at the ASCO 2022 Annual Meeting. The multicohort phase II study (NCT04133636) evaluates the safety and efficacy of Cilta-cel in different myeloma settings, including early lines. Patients in Cohort A include advanced multiple myeloma following 1-3 prior lines of treatment and were lenalidomide-refractory. In contrast, patients in Cohort B had an early relapse after the first therapy that included a proteasome inhibitor and an immunomodulatory medication.
- CAR-T Cell therapies are broadly accepted in the relapsed/refractory patient pool (Abecma and Carvykti logo have been FDA approved for patients with multiple myeloma who have received four prior lines of therapies), but companies are attempting to broaden their prescription and leverage on the early lines of settings. Carvykti/Cilta-Cel has demonstrated early, substantial, and long-lasting responses in heavily pretreated patients with Multiple Myeloma, leading to United States Food and Drug Administration (FDA) approval.
- Although Janssen and Legend biotech primarily targeted the later line of multiple myeloma, the CARTITUDE 2 trial ASCO result suggests that CAR-T cell therapy could be offered in early lines.
Also read Market Research Reports 2022 by Delveinsight
DelveInsight's "Medical Marijuana Market Report 2032" offers an in-depth understanding of the Medical Marijuana epidemiology, pipeline, and market trends in the 7MM.
DelveInsight's Psoriasis Vulgaris Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Psoriasis Vulgaris, historical and forecasted epidemiology as well as the Psoriasis Vulgaris market trends in 7MM.
DelveInsight’s“UK Healthcare Outlook Report, 2022,” provides comprehensive insights about the healthcare scenario, regulatory policies and reimbursement landscape in UK.
DelveInsight's Atrial Flutter Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Atrial Flutter, historical and forecasted epidemiology as well as the Atrial Flutter market trends in 7MM.
Oncolytic Virus Cancer Therapy Pipeline
"Oncolytic Virus Cancer Therapy" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action.
Bone Metastasis In Solid Tumors Market
DelveInsight's Bone Metastasis In Solid Tumors Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Bone Metastasis In Solid Tumors, historical and forecasted epidemiology as well as the Bone Metastasis In Solid Tumors market trends in 7MM.
DelveInsight's Shigellosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Shigellosis, historical and forecasted epidemiology.
Stem Cell Market Research Report provides comprehensive insights into the Stem Cell Market Size, Share, Key Companies, Competitive Analysis as well as the Market Forecast
Tropical Spastic Paraparesis Market
DelveInsight’s Tropical Spastic Paraparesis (TSP) Market Insights, Epidemiology and Market Forecast - 2032 report provides the detailed overview of the disease.
Urology Ultrasounds Devices Market
DelveInsight's 'Urology Ultrasounds Devices Market Insights, Competitive Landscape and Market Forecast-2027' report delivers an in-depth understanding of Urology Ultrasounds Devices.
Cannabis Use Disorder Pipeline
Cannabis Use Disorder (CUD) Pipeline Insights, 2022 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects.
